Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
33.77
-0.09 (-0.27%)
At close: Mar 2, 2026, 4:00 PM EST
33.12
-0.65 (-1.92%)
Pre-market: Mar 3, 2026, 8:01 AM EST
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 37.25, with a low estimate of 26 and a high estimate of 45. The average target predicts an increase of 10.31% from the current stock price of 33.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $38 → $42 | Strong Buy | Maintains | $38 → $42 | +24.37% | Feb 18, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $36 → $45 | Strong Buy | Maintains | $36 → $45 | +33.25% | Feb 9, 2026 |
| Barclays | Barclays | Buy Maintains $35 → $38 | Buy | Maintains | $35 → $38 | +12.53% | Jan 30, 2026 |
| Scotiabank | Scotiabank | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +18.45% | Jan 29, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $36 → $38 | Strong Buy | Maintains | $36 → $38 | +12.53% | Jan 29, 2026 |
Financial Forecast
Revenue This Year
17.05B
from 17.26B
Decreased by -1.23%
Revenue Next Year
17.55B
from 17.05B
Increased by 2.97%
EPS This Year
2.79
from 1.21
Increased by 130.28%
EPS Next Year
3.14
from 2.79
Increased by 12.64%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.9B | 18.5B | |
| Avg | 17.0B | 17.6B | |
| Low | 16.2B | 16.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.9% | 8.3% | |
| Avg | -1.2% | 3.0% | |
| Low | -6.3% | -3.2% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 2.97 | 3.32 |
| Avg | 2.79 | 3.14 |
| Low | 2.60 | 2.92 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | 145.6% | 19.1% |
| Avg | 130.3% | 12.6% |
| Low | 114.6% | 4.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.